Biofrontera Inc Warrants (27/10/2026) BFRIW 深 沪
已收盘 02-06 16:00:00 美东时间
0.063
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.063
- 总市值 0
- 52周最高 0.277
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.0251
- 委 比 -33.76%
- 总股本 --
- 历史最高 9.18
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter
01-13 21:31
Biofrontera Locks Databases For Treatment Phase Of Phase 3 Clinical Trial Of Ameluz PDT, Phase 2 Clinical Trial To Treat Moderate To Severe Acne Vulgaris
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database
01-08 21:48
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Biofrontera Inc. successfully locked databases for two clinical studies evaluating Ameluz PDT for treating actinic keratosis (AK) and acne vulgaris on January 5, 2026. These milestones support key regulatory events and aim to expand Ameluz's approved uses in the U.S. AK and acne are the most common skin disorders in the U.S., impacting tens of millions annually. Positive Phase 3 AK study results could lead to an sNDA submission in Summer 2026 to ...
01-08 13:45
Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA approvals for
2025-12-18 21:54
Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key
2025-12-02 21:48
Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98) per share from the
2025-11-13 05:43
Biofrontera Regains Nasdaq Compliance in November 2025
Biofrontera ( ($BFRI) ) has provided an update. Biofrontera Inc. has announced ...
2025-11-11 06:19
Biofrontera Completes Sale of Xepi US License
The latest announcement is out from Biofrontera ( ($BFRI) ). On November 6, 202...
2025-11-07 21:29
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
Biofrontera Inc. has sold its U.S. rights to Xepi® (ozenoxacin) Cream, 1%, to Pelthos Therapeutics Inc., receiving $3 million upfront, $1 million upon commercial availability, and up to $6 million in milestones tied to sales targets. Proceeds will strengthen Biofrontera’s cash position and support growth of its photodynamic therapy platform and Ameluz® expansion. The transaction enables the company to focus on PDT development and profitability. X...
2025-11-07 13:00
